Publications by authors named "N Gogtay"
Background: Meningococcal disease remains an important public health problem globally. We assessed the non-inferiority and the lot-to-lot consistency of a pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5; Serum Institute of India, Pune, India) versus a quadrivalent meningococcal ACWY conjugate vaccine (MenACWY-D) in healthy adults.
Methods: In this observer-blind, randomised, active-controlled, phase 2/3 study, healthy adults aged 18-85 years were recruited from nine hospitals across seven cities in India.
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Hum Vaccin Immunother
December 2024
AZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from Oxford University/AstraZeneca. The non-inferiority of SII-ChAdOx1 nCoV-19 with AZD1222 was previously demonstrated in an observer-blind, phase 2/3 immuno-bridging study (trial registration: CTRI/2020/08/027170). In this analysis of immunogenicity and safety data 6 months post first vaccination (Day 180), 1,601 participants were randomized 3:1 to SII-ChAdOx1 nCoV-19 or AZD1222 (immunogenicity/reactogenicity cohort = 401) and 3:1 to SII-ChAdOx1 nCoV-19 or placebo (safety cohort = 1,200).
View Article and Find Full Text PDFArticle Synopsis
- Low-dose emicizumab has the potential to be a cost-effective treatment for hemophilia A, particularly beneficial in developing countries.
- A study compared the safety and efficacy of low-dose emicizumab (3 mg/kg monthly) against low-dose factor VIII prophylaxis (10-20 IU/kg twice a week) in two groups of patients.
- Results showed that low-dose emicizumab resulted in significantly better outcomes in various measures, with similar treatment costs compared to low-dose FVIII, making it a promising option for improving access to hemophilia treatment.